Author + information
- Li Huakang,
- Zhang Qing,
- Song Zhiyuan and
- Tao Jing
To assess the clinical efficacy and safety of transcatheter coil embolization of small coronary artery fistula (sCAF).
In this prospective study, 90 patients were diagnosed with sCAF on cardiac angiography between November 1, 2011 and March 30, 2015. They were randomly divided into a treatment group (transcatheter coil embolization) and a control group (no transcatheter coil embolization). Clinical data, examination findings, and drug-use information were collected.
Age, gender, clinical symptoms, complications, pathological coronary artery numbers, and sites of fistula origin/termination did not differ between the groups. The rate of symptomatic improvement was higher in the treatment group than in the control group. In each group, 41 patients completed the follow-up. In the treatment group, left atrial, left ventricular, and right ventricular sizes were significantly lower at 3 and 6 months postoperatively than at the baseline (P < 0.05); the left ventricular ejection fraction was higher at 1 and 6 months than at the baseline. In the control group, right ventricular and left atrial sizes markedly increased (P < 0.05); left ventricular and right atrial sizes did not significantly change (P > 0.05). 41 patients in treatment group underwent real-time 3D transthoracic echocardiography and 1 year of follow-up. In these patients, Tmsv16 - SD%, Tmsv12 SD%, and Tmsv6 SD% significantly decreased postoperatively (P < 0.05).
Transcatheter coil embolization of sCAFs is safe and effective, and improves clinical symptoms, cardiac remodeling and cardiac function.